Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Marie Skłodowska-Curie Action · Running

SLC-Mn-HMNDYT2 Identifying and exploiting SLC39A14 regulatory mechanisms for the future development of therapeutics

Coordinator
Medizinische Universitaet Wien, Austria
Runs
1 September 2025 to 31 August 2027
Status
Running
EU funding
€214k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101212417

What the project is doing

In the project's own words, from its summary on CORDIS.

Solute carriers (SLCs) are membrane proteins that mediate the transport of biological and inorganic molecules. SLC39A14 regulates the transport of manganese (Mn) into primarily liver and intestinal cells from the blood. Bi-allelic loss of function (LOF) variants in SLC39A14 lead to an accumulation of blood Mn, which travels to the brain, causes significant deficits in motor function, eventually leads to the patients being non-ambulatory.

Accordingly, these patients are diagnosed with Hypermanganesaemia with dystonia 2 (HMNDYT2) and are treated with Mn chelating agents. This treatment removes excess Mn from the blood

Topics

Who is involved

OrganisationCityCountryRole
Medizinische Universitaet WienWienAustriaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI